Akademik Veri Yönetim Sistemi
61st annual meeting of the International Association of Forensic Toxicologists (TIAFT 2024), Sankt Gallen, İsviçre, 2 - 06 Eylül 2024, ss.163-164
Background & Aims: Opioid use disorder(OUD) is associated with a lifelong struggle to control drug consumption, it is a chronic, recurrent disease. Although medications such as methadone, buprenorphine/naloxone, and naltrexone are highly effective in the treatment of opioid use disorder (OUD), a significant portion of patients experience cravings for the substance, which may lead them to continue illegal opioid use. This contributes to the observation that only 20 to 40% of individuals diagnosed with opioid use disorder are currently receiving treatment. Buprenorphine is considered to have little respiratory side effects at therapeutic doses but still, there are several reports of buprenorphine-related deaths. Furthermore, its prescription formulations improve treatment accessibility, potentially contributing to the development of dependence. Therefore, the accurate determination of buprenorphine in human plasma samples is crucial for effectively monitoring treatment efficacy and adherence. The present study aims to develop a green microextraction approach for the sensitive detection of buprenorphine and its primary metabolite in commercial plasma using HPLC-UV.
Methods: A novel HPLC-UV method was developed utilizing a Kinetex F5 (Phenomenex, USA) analytical column (150 mm × 4.6 mm i.d., 5 µm) and a mobile phase flow rate of 0.75 mL/min. The mobile phase comprised phosphate buffer (15 mM, pH 4) as mobile phase A and acetonitrile as mobile phase B. The gradient program initiated at 90% mobile phase A, with a subsequent linear increase in the mobile phase B proportion until 90% at 10 minutes. Detection was performed at a wavelength of 210 nm, with each sample injected at a volume of 10 µL.
Results & Discussion: The method was validated according to selectivity, linearity, LOD, LOQ, precision, and accuracy criteria specified in the International Council for Harmonisation guidelines. The method was found linear in the concentration range of 0.2-5 µg/mL for both analytes with correlation coefficient (R2) values greater than 0.999. Intra- and inter-day accuracy ranged from -2.58% to -9.91%, while precision for both analytes was below 5.55%. The limits of detection (LOD) and quantification (LOQ) for the method were established using signal-to-noise ratios. The LOD was found to be 0.05 µg/mL and 0.2 µg/mL for both compounds. The lower limit of quantification (LLOQ), defined as the lowest concentration of analyte with accuracy within 12% and precision <5.55%, was determined at 0.2 g/mL for both buprenorphine and norbuprenorphine.
Conclusion: This rapid extraction and analysis method offers a promising approach for simultaneously detecting
buprenorphine and its main metabolite, customizing treatment, and improving its effectiveness. This methodology
can support monitoring treatment efficacy and compliance, especially for individuals at a higher risk of treatment
failure.